RONDONI, MICHELA
 Distribuzione geografica
Continente #
NA - Nord America 2.395
EU - Europa 2.325
AS - Asia 707
AF - Africa 163
Continente sconosciuto - Info sul continente non disponibili 16
SA - Sud America 6
OC - Oceania 2
Totale 5.614
Nazione #
US - Stati Uniti d'America 2.387
IT - Italia 662
GB - Regno Unito 609
SE - Svezia 338
CN - Cina 260
DE - Germania 223
VN - Vietnam 199
UA - Ucraina 122
IN - India 109
FR - Francia 81
IE - Irlanda 80
JP - Giappone 78
RU - Federazione Russa 65
TG - Togo 54
CI - Costa d'Avorio 53
ZA - Sudafrica 41
EE - Estonia 40
CH - Svizzera 28
JO - Giordania 20
BG - Bulgaria 18
FI - Finlandia 16
BE - Belgio 15
EU - Europa 15
SG - Singapore 14
GR - Grecia 11
IR - Iran 10
SC - Seychelles 10
CA - Canada 8
KR - Corea 5
LB - Libano 4
NG - Nigeria 4
NL - Olanda 4
BR - Brasile 3
CL - Cile 3
PL - Polonia 3
PT - Portogallo 3
BD - Bangladesh 2
ES - Italia 2
NZ - Nuova Zelanda 2
RO - Romania 2
SA - Arabia Saudita 2
TR - Turchia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
CZ - Repubblica Ceca 1
KE - Kenya 1
NO - Norvegia 1
UZ - Uzbekistan 1
Totale 5.614
Città #
Southend 557
Fairfield 309
Chandler 288
Ashburn 182
Wilmington 168
Houston 155
Woodbridge 150
Seattle 142
Dong Ket 130
Cambridge 122
Ann Arbor 120
Princeton 105
Jacksonville 80
Dublin 79
Tokyo 69
Florence 58
Padova 56
Lomé 54
Abidjan 53
Milan 51
Bologna 50
Westminster 50
Nanjing 49
Turin 35
Beijing 32
New York 32
Saint Petersburg 32
Rome 30
Berlin 27
Shenyang 25
Bern 23
Jinan 21
Amman 20
Nanchang 20
Hebei 19
Medford 19
San Diego 18
Sofia 18
Bremen 17
Falls Church 15
Helsinki 15
Redmond 14
Brussels 12
Changsha 12
Haikou 12
Jiaxing 12
Mülheim 11
Norwalk 11
Pavia 11
Zhengzhou 11
Boardman 10
Verona 10
Catania 9
Mahé 9
Mountain View 9
Brescia 8
Olalla 8
Singapore 8
Ningbo 7
Palermo 7
Taizhou 7
Toronto 7
Naples 6
Parma 6
Tianjin 6
Bareggio 5
Forlì 5
Abeokuta 4
Andover 4
Chiyoda-ku 4
Dehradun 4
Francofonte 4
Los Angeles 4
Reggio Emilia 4
Cesena 3
Costa Mesa 3
Des Moines 3
Faenza 3
Fremont 3
Hamamatsu 3
Hounslow 3
Kunming 3
Lanzhou 3
Lausanne 3
Louvain 3
Monza 3
Pescara 3
Salerno 3
Seoul 3
Taiyuan 3
Torino 3
Trento 3
Zanjan 3
Amsterdam 2
Andria 2
Aranjuez 2
Athens 2
Auckland 2
Bengaluru 2
Bühl 2
Totale 3.827
Nome #
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 441
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 193
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 168
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 166
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 157
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 157
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 156
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 148
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 136
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 130
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 126
Advanced mast cell disease: an Italian Hematological Multicenter experience 125
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 124
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 119
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 115
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 115
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 114
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 112
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 112
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 107
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. 106
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 106
null 104
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia 104
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. 103
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 102
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study. 99
Ultra-Deep Sequencing (UDS) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 98
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 92
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 92
Leucemia mieloide cronica: terapia molecolare 91
Hypereosinophilic syndrome and molecularly targeted therapy. 90
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 88
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. 87
The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors. 87
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 85
Imatinib mesylate in the treatment of hematologic malignancies. 85
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 82
Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant) 80
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 79
null 76
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 76
HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING IDENTIFIES NOVEL UNIPARENTAL DISOMY AND FOCAL COPY NUMBER ALTERATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) 74
Soft tissue and skeletal involvement in FIP1L1-PDGFR-A positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission 73
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 72
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 71
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 68
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 66
Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients. 63
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly 62
Strategies in the treatment of acute myeloid leukemia. 57
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 40
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. 26
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 26
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 16
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 10
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders 10
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience 4
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 4
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 4
Totale 5.779
Categoria #
all - tutte 13.017
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.017


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201962 0 0 0 0 0 0 0 0 0 0 0 62
2019/20201.473 218 42 18 107 143 135 172 186 198 90 72 92
2020/2021810 151 60 11 47 20 66 20 37 71 54 37 236
2021/20221.006 94 17 63 117 94 84 17 66 37 75 187 155
2022/20231.365 160 233 52 173 66 96 50 65 224 28 171 47
2023/2024544 29 63 37 42 44 126 43 60 23 26 28 23
Totale 5.779